全膝关节置换术后镇痛:关节周围脂质体布比卡因注射对比关节腔内布比卡因输注导管——双盲随机对照试验
结果显示ON-Q*组并不比Exparel组消耗更多麻醉药品(p=0.641),平均差异为0.5吗啡当量(95%CI=-1.7至+2.8)。除行走时疼痛和物理治疗时疼痛两项次要指标外,两组在疼痛及其他次要结局上无显著差异,上述两项差异约1分VAS, favoring ON-Q*组,但作者认为不太可能具有临床相关性。
要点
- 主要结局累积麻醉药品消耗量两组无显著差异,ON-Q*组平均10.4吗啡当量 vs Exparel组10.9(p=0.641)。
- 行走时疼痛和物理治疗时疼痛两项VAS评分ON-Q*组优于Exparel组约1分(p=0.019和p=0.010),作者认为不太可能具有临床相关性。
- 两组在恶心、便秘、呕吐等术后副作用及研究相关并发症、患者满意度、住院时长上均无差异。
核心结论
- 以麻醉药品消耗量(主要结局)衡量,Exparel(脂质体布比卡因)并不优于ON-Q* Pain Relief System。
- 在两项活动相关疼痛的次要指标上,ON-Q*组有小幅但显著的差异(约1分VAS),作者认为这些差异不太可能具有临床相关性。
- 局部麻醉方式的选择应基于安全性、便利性和成本考虑的综合考量。
研究设计与样本
- 双盲、随机、对照的优效性试验。
- 患者随机分配至ON-Q* Pain Relief System泵输注布比卡因盐酸盐组(n=96)或Exparel(脂质体布比卡因)注射组(n=104)。
- 主要结局为术后第0至3天累积麻醉药品消耗量;住院期间数据从院内记录回顾性收集,出院后通过患者问卷调查收集。
主要发现
- ON-Q*组与Exparel组麻醉药品消耗量无显著差异(p=0.641),平均差异0.5吗啡当量(95%CI=-1.7至+2.8);ON-Q*组平均10.4吗啡当量(95%CI=8.7至12.0),Exparel组平均10.9(95%CI=9.3至12.5)。
- 除行走时疼痛(p=0.019)和物理治疗时疼痛(p=0.010)外,其他疼痛次要指标两组均无显著差异;上述两项在VAS上ON-Q*组优于Exparel组约1分。
- 术后副作用(恶心、便秘、呕吐)、研究相关并发症发生率、患者满意度及住院时长两组均无差异。
关键数值与推荐
- 主要结局累积麻醉药品消耗量:ON-Q*组平均10.4吗啡当量(95%CI=8.7至12.0)vs Exparel组平均10.9(95%CI=9.3至12.5),平均差异0.5吗啡当量(95%CI=-1.7至+2.8),p=0.641。
- 行走时疼痛VAS评分ON-Q*组优于Exparel组约1分(p=0.019)。
- 物理治疗时疼痛VAS评分ON-Q*组优于Exparel组约1分(p=0.010)。
- 证据等级:治疗性I级。
临床怎么用
- 原文结论指出局部麻醉方式的选择应基于安全性、便利性和成本考虑的综合考量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intra-articular bupivacaine hydrochloride (HCl) infusion catheters and periarticular injections of liposomal bupivacaine are often used as postoperative local anesthetics. The purpose of this study was to compare the efficacies of these local anesthetics following total knee arthroplasty. METHODS: This study was a superiority trial with a randomized, controlled, double-blinded design. Patients were randomly assigned to either delivery of bupivacaine HCl by the ON-Q* Pain Relief System pump (n = 96) or by an injection of Exparel (liposomal bupivacaine) (n = 104). The primary outcome of this study was cumulative narcotic consumption on postoperative days 0 through 3. Narcotic consumption data were collected retrospectively from in-hospital records while patients were in the hospital. Following discharge, narcotic consumption data were gathered from patient surveys, as were secondary outcomes measures. RESULTS: We did not identify greater narcotic use in the ON-Q* group compared with the Exparel group (p = 0.641). The mean difference between the groups was 0.5 morphine equivalent (95% confidence interval [CI] = -1.7 to +2.8), with the ON-Q* group consuming an average 10.4 morphine equivalents (95% CI = 8.7 to 12.0) compared with 10.9 (95% CI = 9.3 to 12.5) in the Exparel group. There were no significant differences between groups with regard to any of the secondary measures of pain with the exception of pain while walking and pain with physical therapy (p = 0.019 and p = 0.010, respectively), both of which showed an approximately 1-point difference in favor of the ON-Q* group on a visual analog scale (VAS). There were also no differences in the postoperative side effects, including nausea, constipation, or vomiting, or in the rates of study-related complications, patient satisfaction, or length of hospital stay. CONCLUSIONS: Exparel did not have superior efficacy compared with the ON-Q* Pain Relief System as reflected by narcotic consumption, our primary outcome. There were small significant differences, in favor of the ON-Q* group, in 2 secondary measures of pain during activity, but these approximately 1-point VAS differences are unlikely to be clinically relevant. The choice of a local anesthetic modality should be based on a combination of safety, convenience, and cost considerations. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
引用
- Smith EB, Kazarian GS, Maltenfort MG, et al. Periarticular Liposomal Bupivacaine Injection Versus Intra-Articular Bupivacaine Infusion Catheter for Analgesia After Total Knee Arthroplasty: A Double-Blinded, Randomized Controlled Trial. J Bone Joint Surg Am. 2017. PMID: 28816893. doi:10.2106/JBJS.16.00571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。